Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic Profiling of Peripheral T-cell Lymphoma

ABSTRACT: Genomic Profiling of Peripheral T-cell Lymphoma

PROVIDER: PRJNA601014 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genomic Profiling of Peripheral T-cell Lymphoma

Project description:Genomic Profiling of Peripheral T-cell Lymphoma

| PRJNA601013 | ENA

Peripheral T-cell Lymphoma gene expression profiling

Project description:Peripheral T-cell Lymphoma gene expression profiling

| PRJNA548345 | ENA

Peripheral T-cell Lymphoma gene expression profiling

Project description:Peripheral T-cell Lymphoma cases along with normal T-cells were subjected to gene expression profiling by means of a DASL array. The cases included both PTCL/NOS and Lennert Lymphoma.

2019-09-19 | GSE132550 | GEO

Gene expression profiling of peripheral T-cell lymphoma including gamma delta T-cell lymphoma

Project description:We performed gene expression profiling in 34 peripheral T-cell lymphoma, including 7 cases of gamma delta T-cell lymphoma to identify a unique T-cell receptor signature gene set for classification of gamma delta T-cell lymphoma and alpha beta T-cell lymphoma.

2008-10-15 | GSE11946 | GEO

Identification of multiple subclones in Peripheral T-cell Lymphoma, Not Otherwise Specified with genomic aberrations

Project description:Genomic aberration profiles of Peripheral T-cell Lymphoma, Not Otherwise specified (clinical samples)

2012-05-31 | E-MTAB-998 | biostudies-arrayexpress

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Project description:This phase I trial studies the side effects and the best dose of alisertib when given together with vorinostat in treating patients with Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, or peripheral T-cell lymphoma that has come back. Alisertib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

| 2123001 | ecrin-mdr-crc

Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers

Project description:Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers

| PRJNA757742 | ENA

Single Cell Genomic Analysis of Lymphoma

Project description:Single Cell Genomic Analysis of Lymphoma

| PRJNA671265 | ENA

Single Cell Genomic Analysis of Lymphoma

Project description:Single Cell Genomic Analysis of Lymphoma

| PRJNA671264 | ENA

A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling

Project description:The distinction between the Burkitt lymphoma and diffuse large B-cell lymphoma is imprecise using current diagnostic criteria. We applied transcriptional and genomic profiling to molecularly define Burkitt lymphoma. Gene expression profiling employing Affymetrix GeneChips (U133A) was performed in 220 mature aggressive B-cell lymphomas, including a core group of eight Burkitt lymphomas, which fulfilled all diagnostic criteria of the WHO classification. A molecular signature of Burkitt lymphoma was generated. Chromosomal abnormalities were detected by interphase fluorescence in-situ hybridization and array comparative genomic hybridization. The molecular Burkitt lymphoma signature identified 44 cases. Fifteen of these cases lacked a morphology typical for Burkitt/Burkitt-like lymphoma. The vast majority (88%) of the 176 lymphomas without the molecular Burkitt lymphoma signature represented diffuse large B-cell lymphomas. In 20% of these cases a MYC break was detectable which was associated with complex chromosomal changes. Our molecular definition of Burkitt lymphoma sharpens and extends the spectrum of Burkitt lymphoma. In mature aggressive B-cell lymphomas without a Burkitt lymphoma signature, a chromosomal break in the MYC locus proved to be associated with adverse clinical outcome. Keywords: Gene expression

2006-06-07 | GSE4475 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data